Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs
June 26, 2024 16:05 ET
|
Neurona Therapeutics
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs
Crossject met en perspective le potentiel de ZEPIZURE® à la lumière de l'étude de référence RAMPART et de sa propre étude de bioéquivalence récemment publiée.
June 26, 2024 01:30 ET
|
CROSSJECT
L'étude de référence RAMPART a établi l'injection intramusculaire (IM) de midazolam comme le standard pour la gestion d’urgence préhospitalière des crises d'épilepsie par rapport à l'injection...
Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study
June 26, 2024 01:30 ET
|
CROSSJECT
Landmark RAMPART study established midazolam intramuscular (IM) injection as a standard of care in the pre-hospital emergency management of epilepsy crises compared to traditional benzodiazepine...
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
June 11, 2024 16:05 ET
|
Neurona Therapeutics
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
London Research & Pharmaceuticals (LRP) Presents the Advancement of LRP-661, Their Lead Drug Candidate, at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) Conference in Madrid, Spain, 5-8 May 2024
June 10, 2024 14:33 ET
|
London Research and Pharmaceuticals
London Research & Pharmaceuticals Presents Advancement of LRP-661, Their Lead Drug Candidate, at the New Antiepileptic Drug Conference in Madrid, Spain
Rapport Therapeutics Announces Pricing of Initial Public Offering
June 06, 2024 18:54 ET
|
Rapport Therapeutics, Inc.
BOSTON and SAN DIEGO, June 06, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational...
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
May 28, 2024 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference
May 28, 2024 08:00 ET
|
Neurona Therapeutics
Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 15, 2024 08:30 ET
|
Avenue Therapeutics
– Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 – MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue”...
NeuroSigma Announces Acceptance into 2024 Cohort of the KidsX Accelerator Program
May 09, 2024 09:00 ET
|
NeuroSigma, Inc.
LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. today announced its acceptance into the 2024 cohort of the KidsX Accelerator Program. KidsX is a global leader in pediatric digital...